DetermaRx and DetermaIO
DetermaRx is a genomic test performed on formalin fixed paraffin embedded tissue from patients that have been recently resected for early stage non-squamous, non-small cell lung cancer. The results stratify patients into low, intermediate or high risk of recurrence, and physicians can utilize those results to tailor treatment and surveillance strategies. The test has been approved by Medicare f or patients with Stage I-IIA non-squamous NSCLC
DetermaIO is a potentially transformative immunotherapy diagnostic that comprehensively measures immune response in a tumor specimen. In published studies, DetermaIO outperformed both PD-L1 and Tumor Mutational Burden in identifying responders to immune checkpoint inhibitors....
More Info Less Info